GlassScriptPhysician profile
Christopher M Pavone
NPI 1902059470
$7,175.28
in general payments reported to CMS, 2019-2025
12 companies · $4,764 in 2025
The $4,764 reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $214 · 2020: $105 · 2021: $130 · 2022: $476 · 2023: $1,039 · 2024: $449 · 2025: $4,764.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,375 · Food and Beverage: $1,616 · Travel and Lodging: $647 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $613.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,375.00 |
| Food and Beverage | $1,615.89 |
| Travel and Lodging | $647.12 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $613.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $5,506.45 | 2019-2025 | Misight Contact Lens, Myday Contact Lens |
| Bausch & Lomb Americas INC. | $634.83 | 2023-2025 | Infuse, Miebo, Xiidra |
| Alcon Vision LLC | $367.79 | 2022-2025 | Precision 1, Total30, Tryptyr |
| Johnson & Johnson Vision Care, INC. | $158.90 | 2022-2023 | Acuvue |
| Tarsus Pharmaceuticals, INC. | $126.55 | 2025 | Xdemvy |
| Oyster Point Pharma, INC. | $104.46 | 2022-2023 | Tyrvaya |
| Astellas Pharma US INC | $97.09 | 2024 | Izervay |
| Dompe US, INC. | $65.25 | 2023-2025 | Oxervate |
| Sight Sciences, INC. | $37.03 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $31.09 | 2019 | |
| Sun Pharmaceutical Industries INC. | $26.44 | 2024 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Pavone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.